About Nanobiotix S.A.
https://www.nanobiotix.comNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer.
CEO
Laurent Levy
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public December 11, 2020
Method of going public IPO
Full time employees 108
Ratings Snapshot
Rating : C+
Discounted Cash Flow 4
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $26
Target Low $26
Target Median $26
Target Consensus $26
Institutional Ownership
JOHNSON & JOHNSON
Shares:5.62M
Value:$121.08M
BLACKROCK INC.
Shares:239.01K
Value:$5.15M
GEODE CAPITAL MANAGEMENT, LLC
Shares:10.18K
Value:$219.26K
Summary
% Of Shares Owned 12.39%
Total Number Of Holders 13
Showing Top 3 of 13
Market Cap $948.02 M
52w High $30.35
52w Low $2.93
P/E -16.95
Volume 43.77K
Outstanding Shares 47.47M
About Nanobiotix S.A.
https://www.nanobiotix.comNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $26.64M ▲ | $25.83M ▲ | $-5.38M ▲ | -20.21% ▼ | $-0.11 ▲ | $1.09M ▲ |
| Q4-2024 | $-20.9M ▼ | $23.84M ▼ | $-46.26M ▼ | 221.36% ▲ | $-0.98 ▼ | $-35.08M ▼ |
| Q2-2024 | $9.29M ▼ | $32.94M ▼ | $-21.87M ▼ | -235.46% ▼ | $-0.46 ▼ | $-23.24M ▼ |
| Q4-2023 | $32.91M ▲ | $34.32M ▲ | $-11.6M ▲ | -35.25% ▲ | $-0.3 ▲ | $1.41M ▲ |
| Q2-2023 | $3.29M | $28.66M | $-28.1M | -853.29% | $-0.8 | $-24.64M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $28.82M ▼ | $45.17M ▼ | $114.13M ▼ | $-68.95M ▼ |
| Q4-2024 | $49.74M ▼ | $67.42M ▼ | $133.12M ▲ | $-65.7M ▼ |
| Q2-2024 | $66.33M ▼ | $86.68M ▼ | $108.46M ▲ | $-21.78M ▼ |
| Q4-2023 | $75.28M ▲ | $93.9M ▲ | $95.74M ▲ | $-1.84M ▲ |
| Q2-2023 | $21.63M | $40.41M | $94.19M | $-53.78M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-5.38M ▲ | $-17.41M ▼ | $-162K ▲ | $-2.83M ▼ | $28.82M ▼ | $-17.56M ▼ |
| Q4-2024 | $-46.26M ▼ | $-13.71M ▼ | $-455K ▲ | $-2.48M ▲ | $54.21M ▲ | $-14.07M ▼ |
| Q2-2024 | $-21.87M ▼ | $-5.84M ▼ | $-500K ▼ | $-2.65M ▼ | $-4.47M ▼ | $-6.33M ▼ |
| Q4-2023 | $-11.6M ▲ | $4.8M ▲ | $-22K ▲ | $48.91M ▲ | $53.65M ▲ | $4.79M ▲ |
| Q2-2023 | $-28.1M | $-17.58M | $-327K | $-1.84M | $-16.95M | $-17.9M |
Revenue by Products
| Product | Q2-2021 |
|---|---|
 Other Sales | $0 ▲ |
 Services | $0 ▲ |
CEO
Laurent Levy
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public December 11, 2020
Method of going public IPO
Full time employees 108
Ratings Snapshot
Rating : C+
Discounted Cash Flow 4
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $26
Target Low $26
Target Median $26
Target Consensus $26
Institutional Ownership
JOHNSON & JOHNSON
Shares:5.62M
Value:$121.08M
BLACKROCK INC.
Shares:239.01K
Value:$5.15M
GEODE CAPITAL MANAGEMENT, LLC
Shares:10.18K
Value:$219.26K
Summary
% Of Shares Owned 12.39%
Total Number Of Holders 13
Showing Top 3 of 13